nanoform
small is powerful®

Nanoform Management Presentation

Q2 and H1 2022 online presentation and conference call

August 25th, 2022 – 15.00 Helsinki time

Our proprietary nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics. We support all phases of drug development, accelerating time to clinic for GMP manufacture while also increasing possibilities and probabilities of success in taking the product to market. Nanoform's technology offerings have the capability to transform the pharmaceutical industry.

Disclaimer

Forward-Looking Statements

This presentation contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2021 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Short introduction to Nanoform

Nanoform in a Snapshot

The Share

- Listed June 4th, 2020, on Nasdaq First North Premier Growth Market in Helsinki and Stockholm
- Tickers: NANOFH and NANOFS
- Significant Nordic, European and US institutional ownership
- All press releases: https://nanoform.com/en/section/media/press-releases/

Nanoform

- Global experts in nanotechnology and drug particle engineering
- ~140 employees, ~30 nationalities, ~40 with PhD degree
- Headquartered in Finland with additional senior staff and board members in Denmark, France, Portugal, Sweden, UK, and US
- >3000m² manufacturing site in Helsinki for nanoforming API's
- Strong balance sheet, more than EUR 80m in cash, no debt

Platform Technology

- CESS® technology for small molecules (chemical compounds) discovered in 2012
- Technology for large molecules (biological compounds) launched in 2020
- Nanoform's clinical results confirm value proposition to the pharma industry

API = Active Pharmaceutical Ingredient
CESS® = Controlled Expansion of Supercritical Solutions
GMP = Good Manufacturing Practice

The structural pharma R&D problem

Less than 50 drugs approved in the US annually on average…

Annual number of novel drug approvals by FDA 2010-2021



…while the global pharma industry R&D expenditure exceeds $200B

Global pharmaceutical R&D spending 2010-2026E (USDbn)



➢ **A game changer in particle design is needed to improve R&D yield**

Source: U.S. Food and Drug Administration (FDA); IQVIA Institute for Human Data Science

Global pharma market projected to reach USD 1.8tn by 2026

Global medicine spending 2010-2026E (USDtn)

Covid net impact 2020-2026E: +$134B (Covid vaccines and therapeutics +$309B and disruptions in other segments -$175B)



➢ **Significant market potential in improving the properties of existing drugs**

Source: IQVIA Institute for Human Data Science; EvaluatePharma

Low bioavailability is the key issue

Poor bioavailability and low efficacy most common reasons for drug failure

Reasons for drug failure in pre-clinical trials (share of molecules)



Majority of new drugs suffer from poor solubility



➢ **Nanoform can enhance the pharma industry output by targeting poorly soluble drugs**

Source: GlobalData 2009, Cutting Edge Water-based Nanotechnology in Drug Development (Reasons for drug failure); Nikolakakis & Partheniadis (2017), Self-Emulsifying Granules and Pellets: Composition and Formation Mechanisms for Instant or Controlled Release (Share of poorly soluble drugs)

1) Classification of drug substance according to Biopharmaceutics Classification System (BCS)

Nanoform is here to fill the gap

The solution to low bioavailability is to decrease the particle size of the Active Pharmaceutical Ingredient (API)

Giving unsuccessful drug candidates a second chance

>58 000
failed drugs in the last 40 years*

Improving existing drugs

>5 800
existing drugs*

Enabling new drugs

>19 000
drugs in development*

Nanoform's CESS® is the only technology that can manufacture nanoparticles without solvents, excipients, and complex production processes

API = Active Pharmaceutical Ingredient
CESS® = Controlled Expansion of Supercritical Solutions
**Source: Nanoform and Pharmaprojects® | Informa, 2021*

Particle size is key

Smaller particle size can improve a drug's bioavailability



- The surface area increases 30 fold from a 10 micron[1] sized particle once the particle size is reduced to 100nm
- Reduction of particle size down to 50nm increases the surface area by 1,000 fold



Pre-nanoforming | Post-nanoforming

- Smaller particles have a larger surface area
- Larger surface area of particles enables better bioavailability of a drug
- Improved bioavailability implies better absorption of a drug by the body's circular system
- CESS® can produce API with large surface areas which can significantly improve the bioavailability of drugs

CESS® produced nanoparticles have a larger surface area and as such improved bioavailability

Source: Company information
1) 1 micron = 1,000nm

Small molecules - Patented technology

Controlled Expansion of Supercritical Solutions - CESS®



Supercritical CO_2 extraction schematic diagram

1. Supercritical CO_2 is guided into a pressure vessel loaded with API
2. Increasing the pressure and temperature in the vessel dissolves the API in supercritical CO_2
3. The CO_2 and the API are released from the pressure vessel and the flow, pressure and temperature profiles are accurately controlled
4. In the tube, the pressure and temperature is controlled to achieve a stable nucleation phase and formation of nanoparticles at the nozzle
5. In a collection vessel the CO_2 is sublimated resulting in final nanoparticles ready for collection and formulation

➢ **Relatively simple process developed through combining deep knowledge in physics, chemistry, and pharma**

The CESS® technology platform was described in detail in the IPO prospectus (offering circular) on pages 76-80. The prospectus can be found via the following link: https://nanoform.com/en/ipo-materials/

Small molecules - Small is powerful®



Large molecules - Small is now possible in biologics too

Our unique **biological nanoforming technology** can produce drug particles as small as 50 nm in diameter while retaining biological activity. It is a gentle bottom-up process, and its effectiveness has been demonstrated on peptides and proteins in the 6 kDa* – 150 kDa range. We can engineer particle sizes to specific requirements. Our advanced technology can be applied across the biologics field to potentially:



***1 kDa = One thousand daltons. A dalton is the weight of a hydrogen atom. Kilodalton is the standard unit used to represent the weight of large molecules such as proteins.**

Simplified value chain

High level overview of Nanoform's value chain and business model

Clients

- **Global large pharma**
- **Mid-sized and specialty pharma**
- **Biotech**



Launch of new drugs, improving existing drugs & reducing clinical attrition

nanoform
small is powerful®

Revenue

- **Fixed fee per project**
- **Royalty as a % based on drug sales or supply price per kg**

➢ **Nanoform nanoforms APIs for the pharma and biotech industry using its patented CESS® technology**

API = Active Pharmaceutical Ingredient
CESS® = Controlled Expansion of Supercritical Solutions
GMP = Good Manufacturing Practice

CEO review

Selected Company Milestones 2022 YTD

2022 YTD

US GMP MANUFACTURING ANNOUNCEMENT

STARMAP® ONLINE LAUNCH

UPSCALING CO2 INPUT TO GMP MANUFACTURING BY 1000X

ASTRAZENECA PLC CONCLUDES TECHNOLOGY EVALUATION WITH POSITIVE OUTCOME

NEW HALF YEAR RECORD: 13 NEW PROJECTS WITH 12 CLIENTS AND REVENUE RECOGNISED FROM 28 PROJECTS

NANOFORM PARTNERS WITH PHARMANOVIA

GMP = Good Manufacturing Practice

Isolator to GMP-2 manufacturing line arrived August 9th, 2022

Nanoform Quality Director Johanna Kause and Engineering Project Coordinator Kari Steffen supervising isolator delivery

An isolator allows the containment of the pharmaceutical process, a protected environment, free of viable microorganisms and ensuring that the production area and the personnel/environment are separate.

Nanoform near-term business targets 2022

Topic	Target	Status
GMP Line Capacity	***"2 new GMP lines in 2022"***	***On track***
Biologics pilot-GMP	***"Biologics pilot line for GMP in 2022"***	***On track***
Non-GMP Projects	***"At least 20 new customer non-GMP projects in 2022"***	***On track***
GMP Projects	***"At least 3 new customer GMP projects in 2022"***	***On track***

GMP = Good Manufacturing Practice

Nanoform mid-term business targets 2025

>70 new APIs per year

35 lines of which 7-14 are GMP compliant

200-250 employees

>90% gross margin

Cash flow positive

API = Active Pharmaceutical Ingredient
GMP = Good Manufacturing Practice


Commercial

Global drug R&D pipeline size and growth



Source: Pharmaprojects®, January 2022

Global number of companies with active pipelines



Source: Pharmaprojects®, January 2022

Chicago
Vice President
Business Development
Sergie Letser

PORTON
Johnson Matthey
CAMBRIDGE MAJOR LABORATORIES

San Diego
Vice President
Business Development
Dr. Chris Worrall

Johnson Matthey
MERCK
SIGMA-ALDRICH

New York
Vice President
Business Development
Eric Peter

Hovione
patheon

Cambridge
Chief Commercial Officer
Christian Jones

Dr.Reddy's
gsk
Prosonix
Johnson Matthey

Lisbon
Business Development
Manager
Joana Moreira da Silva

Hovione

Bordeaux
Vice President
Business Development
Frédérique Bordes-Picard

AstraZeneca
Capsugel
Lonza

Helsinki
Commercial Associate
Britta Madison

gsk
Janssen
Biocon

Oxford
Commercial Insights Officer
Dr. Jamie Unwin

Durham
Vice President
Business Development
Dr. Nathalie Huther

ARCINOVA
Johnson Matthey
SIGMA-ALDRICH
Quotient Sciences

London
Business Development
Manager
Dr. Hui Yi Tee

Bristol Myers Squibb
Janssen

- Experienced global sales team driving momentum and the shift in company focus from technology development to commercialization

Good momentum with customers and projects

H1/2020

5 new non-GMP projects signed

5 customers
(4 EU + 1 US)

H1/2021

8 new non-GMP projects signed

6 customers
(3 EU +3 US)

H1/2022

13 new non-GMP projects signed

12 customers
(6 EU + 6 US)

Commercial Relationships Q4/2019-Q2/2022

***7* major pharma companies**

e.g. Astra Zeneca and Boehringer Ingelheim



***21* mid-sized, specialty pharma & biotech companies**

e.g. Pharmanovia, Herantis and TargTex

including

5 new in Q2/2022

***1* co-development**

***3* collaborations**

e.g. Aprecia and Celanese Corp

Successful technology evaluation by AstraZeneca Plc

In Q2 2022 **AstraZeneca Plc** concluded its thorough technology evaluation of **Nanoform**'s proprietary ***CESS® Technology***.

The outcome of the technology evaluation was positive, and AstraZeneca is now ***moving forward to an identification and implementation stage for the technology where it will look to implement the technology on current and future development projects***.

nanoform
small is powerful®

Nanoform partners with Pharmanovia

Press release
Nanoform Finland Plc
July 14th, 2022

Nanoform and Pharmanovia to breathe new life into iconic medicines

Helsinki, Finland – Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company, today announced that it has partnered with Pharmanovia, **a fast-growing specialty pharma business with a portfolio of over 20 branded drugs in 140 markets**.

The new strategic partnership aims to add value to branded prescription medicines. **Pharmanovia will look to apply Nanoform's proprietary nanoparticle technologies and formulation know-how to leading established pharmaceutical brands**.

The partnership starts with an iconic branded medicine where both parties see value in enhancing bioavailability for patient benefit. The value of the *stage-gated agreement* is according to Nanoform's business model for non-GMP and cGMP work.

Nanoform - Attractive revenue model

Predictable revenue streams through capitalizing the entire pharmaceuticals value chain

Phase	Proof of Concept / Proof of Process	Phase I – III trials	Drugs on the market
Certification	Non-GMP	GMP	GMP
Description	➢ *Proof of concept study* - assessment of the possibility to nanoform a specific API ➢ *Proof of process study* - definition of parameters to establish the optimal process and controls for a specific API	➢ API for clinical trials are manufactured in Nanoforms GMP facility ➢ Supply of material for customers' Phase I, II and III trials ➢ Nanoform gets paid regardless of the outcome of the trials	➢ Drugs that have passed the trials and reached commercialization ➢ In practice, if a company has taken its drug through Phase II trials, it is difficult to switch manufacturer ➢ Significant potential from patent extension (505b2 projects) of drugs already on the market
Revenue model	Fixed fee per project *Estimated project fee of EUR 50-500k per API per project*	Fixed fee per project *Estimated project fee of EUR 0.5-10m per API per phase*	Royalty as a % based on drug sales or supply price per kg *Estimated royalty fee of 1-20%*

➢ **Attractive business model with diversified risk profile due to not having to carry the cost & risk of drug development or being dependent on a single drug**

Revenue drivers and industry attrition rates

Nanoform pre-clinical and clinical revenue drivers

	Non-GMP	GMP
Proof of Concept (PoC)	➢ # of active customers ➢ # of APIs per customer ➢ Price per PoC per API	
Phase I, II & III		➢ Attrition between previous and current phase ➢ Price per phase per API ➢ Time lag between previous and current phase ➢ # of customers with 505(b)(2) strategy ➢ Proportion of new drug candidates and 505(b)(2) APIs
Proof of Process (PoP)	➢ Attrition between PoC and PoP ➢ Price per PoP per API ➢ Time lag between PoC and PoP	
Drugs on the market		➢ # of drugs on the market using CESS® ➢ License fee & royalty level per drug ➢ Net revenues per drug ➢ Time lag Phase II and market (505b2) ➢ Time lag Phase III and market ➢ Speed of uptake on market

Global Pharmaceutical industry's pre-clinical and clinical success rates



Timeline (years)	Pre-clinical	Phase I	Phase II	Phase III	Approval	Total
New drugs	~1-4	~2	~2	~3-4	~1	~9-13
Existing drugs	-	Clinical development for 505(b)(2) ~2-5			~1	~3-6

Source: Company information; Takebe, Imai & Ono (2018), Clinical and Translational Science (11) (Pre-clinical to Phase I); Biotechnology Innovation Organization, Biomedtracker and Amplion, Clinical Development Success Rates 2006-2015 (Clinical success rates); Kaur, Sharma & Sharma (2014), Journal of Drug Delivery and & Therapeutics (4) (Timeline); The Pharmaceutical Journal, Drug Development: The Journey of a Medicine from Lab to Shelf (Timeline); Camargo Pharmaceutical Services, Understanding the 505(b)(2) Approval Pathway (Timeline); 1) Non-NMEs often use 505(b)(2) pathway to gain FDA approval, source: Biotechnology Innovation Organization, Biomedtracker and Amplion 2) Academic drug discovery, NME consisting only of small molecules

1Q 2022 Financials

Nr of employees & nr of lines ~ 3x during last 2.5 years





Nr of projects signed in 2Q, 1H and cumulatively





Nr of projects signed ~ 4x (r12m) and 7x (cumul.) during last 2.5 years





Nr of projects generating revenue ~ 5x (r12m) and 2x (per line/year) during last 2.5 years





First half revenue and nr of projects contributing





Quarterly (~6x) and rolling 12 months revenue (~14x) during last 2.5 years





Gross margin above 2025 target, EBITDA to turn as revenue grows faster than costs





IT expenses risen as planned due to investment in new ERP system





Travel back after covid, but digital meetings can save time, energy & the environment





Operational KPI’s

Operational KPI’s

	4–6/2022	4–6/2021	1–6/2022	1–6/2021	1–12/2021	1–12/2020	1–12/2019
Number of new customer projects signed during the period							
Non-GMP	5	2	13	8	16	10	2
GMP					2		
Total number of new customer projects	**5**	**2**	**13**	**8**	**18**	**10**	**2**
Number of lines (end of the period)							
Non-GMP	16	12	16	12	14	8	4
GMP	1	1	1	1	1	1	
Total number of lines (end of period)	**17**	**13**	**17**	**13**	**15**	**9**	**4**
Number of employees (end of period)	143	106	143	106	125	74	43

Financial KPI’s

Financial KPI’s

EUR thousand	4–6/2022	4–6/2021	1–6/2022	1–6/2021	1–12/2021	1–12/2020	1–12/2019
Revenue	890	546	1,650	824	1,955	687	49
Revenue growth %	63%	185%	100%	141%	185%	n.m.	n.m.
Gross profit	820	518	1,519	761	1,792	497	-323
Gross margin	92%	95%	92%	92%	92%	72%	neg.
EBITDA	-5,484	-4,358	-10,057	-8,283	-17,745	-18,196	-6,900
Operating loss	-6,070	-4,841	-11,183	-9,203	-19,705	-19,423	-7,344
Loss for the period	-6,058	-5,340	-11,352	-9,610	-19,690	-19,441	-7,554
Basic EPS (EUR)	-0.08	-0.07	-0.15	-0.14	-0.29	-0.35	-0.19
Net debt	-75,727	-82,563	-75,727	-82,563	-68,070	-54,156	-3,640
Net debt excluding lease liabilities	-83,003	-88,120	-83,003	-88,120	-75,733	-59,977	-6,626
Investments in property, plant, and equipment	-2,759	-1,798	-5,063	-2,658	-7,737	-2,336	-1,804
Operative free cash flow	-8,243	-6,156	-15,120	-10,941	-25,482	-20,532	-8,704
Cash and cash equivalents (end of period)	83,003	88,120	83,003	88,120	75,733	61,025	7,303

Income statement

Condensed interim financial information January–June 2022

Consolidated statement of comprehensive income

EUR thousand	Note	4–6/2022	4–6/2021	1–6/2022	1–6/2021	1–12/2021
Revenue	4	890	546	1,650	824	1,955
Other operating income						0
Materials and services		-70	-28	-131	-63	-162
Employee benefits	7	-4,160	-3,693	-7,636	-6,453	-13,791
Depreciation, amortization and impairment losses	6	-586	-483	-1,127	-920	-1,960
Other operating expenses	5	-2,144	-1,183	-3,939	-2,591	-5,747
Total expenses		**-6,960**	**-5,388**	**-12,833**	**-10,027**	**-21,660**
Operating loss		**-6,070**	**-4,841**	**-11,183**	**-9,203**	**-19,705**
Finance income		263	295	495	1,431	2,585
Finance expenses		-248	-792	-647	-1,836	-2,567
Total finance income and expenses		**15**	**-498**	**-152**	**-405**	**18**
Loss before tax		**-6,055**	**-5,339**	**-11,335**	**-9,609**	**-19,687**
Income tax		-4	-1	-16	-1	-3
Loss for the period		**-6,058**	**-5,340**	**-11,352**	**-9,610**	**-19,690**

1-6/2022 comments

- **Revenue** grew by 100% to EUR 1.65 million in 1H22, stemming from 28 different customer projects (16 projects in 1H21). The impact from the two GMP contracts signed in 4Q21 was yet modest on the revenue recognized. Revenues are recognized over the lifetime of the projects, based on expenses (mostly hours worked) booked for the projects.

- The **gross profit** doubled in line with the revenue as the gross margin stayed unchanged at 92%. The total operating costs grew by 29% compared to 1H21. The IT costs grew by almost EUR 1m due to the ongoing ERP project. Otherwise, the growth in costs was moderate.

- The **headcount** increased by 35% to 143 (106 end of 2Q21), while the employee costs grew by 18%. **Cash position** was EUR 83 million.

5. Other operating expenses

EUR thousand	4–6/2022	4–6/2021	1–6/2022	1–6/2021	1–12/2021
Premises expenses	32	31	63	52	100
IT expenses	798	152	1,189	234	780
Marketing and communication expenses	175	136	342	290	589
Consultant and professional fees	270	272	639	624	1,150
Travel expenses	107	18	167	37	146
Voluntary personnel related expenses	226	149	413	384	745
R&D expenses – external	136	169	366	539	930
Other expenses	400	256	760	432	1,306
Total	**2,144**	**1,183**	**3,939**	**2,591**	**5,747**

The increase in other operating expenses stems mainly from the ongoing ERP project (IT expenses) and increased smaller purchases related to property, plant, and equipment which do not fulfill the activation criteria (other expenses).

Q&A

www.nanoform.com

San Diego - Chicago - New York - Lisbon - Newcastle - Oxford – London - Cambridge - Bordeaux - Stockholm - Helsinki

Appendix

Selection of Nanoform Institutional Shareholders[1]

1) Latest ownerhsip data can be found at https://nanoform.com/en/ownership-structure/

Nanoform educational material

VIDEOS

CPhI Discover 2021 presentation: **"Overcoming Drug Development Challenges with Nanotechnology"** – Nanoform, Johnson Matthey and Quotient Sciences experts shared insights into the power of sparse-data AI in drug development and the collaborative studies investigating the performance of our CESS® technology. https://nanoform.com/en/article/video-cphi-discover-2021-presentation/

Nanotechnology Fireside Chat at Partnerships in Drug Delivery (PODD) 2021: Fireside chat between Nanoform and AstraZeneca representatives discussing the potential of nanoscale medicines and delivery devices to benefit patients. https://nanoform.com/en/articles-videos/ (choose Video 1 on November 26, 2021)

BIO-Europe 2021 fireside chat: Nanoform and Informa Pharma Custom Intelligence representatives discussed – **"(b)(2) or not to be – understanding the commercial returns possible from patient-centric differentiation strategies through the 505(b)(2) pathway."** https://knect365.wistia.com/medias/d87ze36n5k

American Association of Pharmaceutical Scientists (AAPS) webinar: We hosted a webinar "**Tailored API Nanoparticles: How Powerful Can Small Be?"** in partnership with the American Association of Pharmaceutical Scientists (AAPS) - one of their top 5 most popular webinars of 2021! https://player.vimeo.com/video/684197206?h=6dac8c956d

Nanoform's client TargTex: **TargTex CEO João Seixas discusses the value Nanoform's CESS® technology** delivered for TargTex's novel drug candidate targeting glioblastoma. https://nanoform.com/en/articles-videos/

The Nanomed Zone webinar: We showcased the results from our collaboration with Johnson Matthey in our webinar with The Nanomed Zone**: "How CESS® technology stacks up against the competition: the smaller, the better!"** https://nanoform.com/en/article/video-the-nanomed-zone-webinar/

ARTICLES

The power of predictive AI can de-risk drug development and improve efficiency, enabling new and enhanced therapeutics to reach patients more rapidly: we delved into this topic in CHEManager. Discover their insights here, including how our pioneering AI-based STARMAP® platform can help: https://www.chemanager-online.com/en/news/nanoparticle-engineering

Solid Form Strategies for Increasing Oral Bioavailability: We discussed the power of CESS® and other industry-standard techniques with Drug Hunter. https://drughunter.com/resource/solid-form-strategies-for-increasing-oral-bioavailability/

Embracing GMP Manufacturing to Meet Pharma's Future: We discussed our GMP expansion project with DCAT Value Chain Insights. https://www.dcatvci.org/proof/embracing-gmp-manufacturing-to-meet-pharmas-future/

OTHER MATERIALS

Nanoform brochure to pharma industry: https://nanoform.com/en/brochure-november-2021/

Nanoform white paper: **"Strategies for patient-centric differentiation through the USFDA 505(b)(2) pathway":** With faster routes to approval, the volume of 505(b)(2) applications now exceeds that of 505(b)(1). Discover the reasons for this in our white paper. https://nanoform.com/en/wp-content/uploads/sites/2/2022/05/whitepaper-march-2022.pdf

Positive results from first-in-human trial of Nanoformed piroxicam: Overcoming Drug Development Challenges with Nanotechnology: CESS®-nanoformed piroxicam demonstrated the power of CESS® **for improving solubility, dissolution and in vivo absorption**. https://nanoform.com/en/wp-content/uploads/sites/2/2021/05/positive-results-from-first-in-human-trial-of-nanoformed-piroxicam.pdf

International team of highly skilled professionals

~140 employees

~30 nationalities

Balanced combination of experts from business and academia

~40 PhD's from different fields including physics, pharma, and biology



Management team: Multi-disciplinary with international merits

CEO & Co-founder; Ph.D. (applied Physics), MBA
Edward Hæggström
- Professor at the University of Helsinki, Head of Electronics Research Lab. within the Dept. of Physics
- Previously visiting professor at Harvard Medical School, visiting scholar at Stanford University and project leader at CERN
- Has led a large number of scientific projects
- *Current ownership: 5,409,405 shares*

CTO; Ph.D. (Pharmaceutical Technology)
Niklas Sandler
- Previously Vice Rector for Research Affairs and Professor of Pharmaceutical Technology at Åbo Akademi University
- Extensive experience in industry and academia
- **Key area of expertise:** Pharmaceutical product development and material science
- *Current ownership: 20,000 shares and 260,000 options*

CCO; M.Sc. (Chem.)
Christian Jones
- Previously Commercial Director and member of the Senior Leadership Team for the Global Health Sector at Johnson Matthey
- Also senior roles at Dr. Reddy's Global Custom Pharma Solutions and Prosonix
- **Key area of expertise:** Commercial strategy and business development
- *Current ownership: 300,000 options*

Director Human Resources; LL.M
Johanna Tuomisto
- Previously HR Director, Finland at Thermo Fisher Scientific
- Senior Vice President , Administration at Finnvera Oyj, and as a Legal & HR Director and Partner at Evli Bank Plc
- **Key area of expertise:** Human resources
- *Current ownership: 50,000 options*

CFO and member of the Board; B.Sc. (Econ.)
Albert Hæggström
- 20 years of finance and investing experience
- Prior roles include senior positions at Alfred Berg, BNP Paribas, Nordea and SEB
- *Current ownership: 701,135 shares and 400,000 options*

Head of Manufacturing; Ph.D. (Chem.)
David Rowe
- Previously Particle Size Reduction Lead for GlaxoSmithKline
- Has chaired the PSR Centre of Excellence
- **Key area of expertise:** Technical leadership within new chemical entities and commercial assets
- *Current ownership: 290,000 options*

General Counsel; LL.M
Peter Hänninen
- Previously Attorney, Borenius Attorneys
- Successful track-record of advising technology companies from founding to exit in key transactions and collaborations
- **Key area of expertise:** Legal, Compliance, IPR
- *Current ownership: 103,125 shares and 230,000 options*

Board of directors: Top executives from leading industry positions

Miguel Calado

Chairman of the Board

- Previously CFO at international particle engineering CDMO company Hovione Group
- Other previous roles include CFO at PepsiCo International and President International Operations at Dean Foods
- Experienced Board member in both the EU and the US
- *Current ownership: 39,794 shares and 380,000 options*
- **Key experience:**

PEPSICO Hovione Dean FOODS

Albert Hæggström

CFO and Board Member

- 20 years of finance and investing experience
- Prior roles include senior positions at Alfred Berg, BNP Paribas, Nordea and SEB
- *Current ownership: 701,135 shares and 400,000 options*
- **Key experience:**

Alfred Berg BNP PARIBAS Nordea SEB

Mads Laustsen

Board Member

- Over 30 years of experience in pharmaceutical development and manufacturing
- Co-Founder and former CEO of international biologics CDMO company CMC Biologics
- Extensive experience in process development and patenting
- Senior positions within several Danish biotech companies
- *Current ownership: 12,181 shares and 300,000 options*
- **Key experience:**

CMC biologics BACTOLIFE symphogen

Jeanne Thoma

Board Member

- 30+ years of experience in global pharmaceutical and life science leadership
- Prior roles include executive positions at BASF Inc, Lonza AG and SPI Pharmaceuticals
- *Current ownership: 12,181 shares and 38,630 options*
- **Key experience:**

BASF We create chemistry Lonza SPI Pharma An ABF Ingredients Company

STARMAP® and STARMAP® Online

What do we do?

Our STARMAP® Online platform leverages cutting-edge sparse-data AI to pick winners among candidate molecules that are predicted to be best amenable to CESS®-powered Nanoforming and that exhibit optimal production characteristics.

How do we do this?

When existing data alone is not sufficient for generating specific predictions, sparse-data AI comes to the rescue. Our STARMAP® online platform augments experimental results with detailed expert knowledge to allow sensible predictions to be made regarding drug development success. Currently, we are launching a digital version of our CESS® technology that allows us to perform in silico experiments in large quantities and to create predictions of Nanoformability.

Why do we do this?

Our game-changing CESS® technology lies at the heart of our operations and offers a unique opportunity to both bring failed assets back to life again and accelerate APIs to the clinic. The STARMAP® platform can have wide applicability in drug discovery and development as well as in lifecycle management for existing marketed drugs and 505(b)(2) like product development strategies. As CESS® has the potential to drastically improve several characteristics of APIs relative to other technology platforms, we recognize that it is vital to apply STARMAP® widely to rapidly identify for our customers the APIs with the greatest potential for nanoforming success. Additionally, past AI-based technologies were trained on old particle engineering techniques such as micronization, limiting prediction accuracy. This opens up the possibility that previously disregarded drug candidates can be revisited with the latest technology and transformed into a drug development success story.

Latest STARMAP® presentations:
www.nanoform.com/en/starmap/

Small molecules - CESS® Superior to Existing Technologies

CESS® comparison with existing technologies

	Controlled Expansion of Supercritical Solutions (CESS®)	Solid dispersion (e.g. spray drying)	Jet milling	Nanomilling
Description	Extracts API from supercritical CO_2 by applying controlled reduction in pressure	API is dispersed into a solid material, which dissolves when exposed to an aqueous media	Application of energy to physically break down API particles to finer ones	API particle size is reduced in a liquid vehicle via grinding
Particle size	Down to 10nm	300nm-25µm	800nm-10µm	>150nm
Particle formation	Controlled crystalline or amorphous and stable	Amorphous (unstable without excipients)	Unstable (crystalline and amorphous structures)	Unstable (crystalline and amorphous – needs excipient to stabilise)
Ease of formulation	✓	✗	✗	✗
Reproducibility	✓	✓	✗	✗
Free from excipients and solvents	✓	✗	✓	✗
Yield	High	Low	High	Low
Investment	Low	High	Low	Low

Source: Company information; Chimica Oggi: Chemistry Today; Roots Analysis, Pharmaceutical Spray Drying Market, 2014-2024

Achieved near-term business targets

Topic	Target	Status	
GMP Approval	*"GMP approval expected no later than Q3 2020"*	*Achieved - GMP certificate awarded April 2020*	✓
Ongoing Client Intake	*"For 2020, our ambition is to accelerate our growth by winning more new customers than in 2019"*	*Achieved – 4 new customers by July 2020*	✓
First GMP Project	*"Start of first GMP project before year-end 2020"*	*Achieved – First GMP campaign started in October 2020*	✓
Clinical Trials	*"First dosing in humans in 2021"*	*Achieved – First dosing in humans announced December 2020*	✓
Biologics	*"First commercial Biologics PoC project signed in 2021"*	*Achieved – First Biologics PoC agreement signed February 2021*	✓
Non-GMP Line Capacity	*"At least 3 new non-GMP lines in 2021"*	*Achieved – 3 new non-GMP lines ready in Q1 2021*	✓
Customer Projects	*"At least 12 new non-GMP customer projects and at least one new GMP project in 2021"*	*Achieved – 14 non-GMP and 1 GMP project signed by November 2021*	✓

GMP = Good Manufacturing Practice
PoC = Proof of Concept

How small is a nanometer (nm)?



Nanoforming - platform enabler across drug delivery



nanoform
small is powerful®

FURTHER ENQUIRIES

CFO Albert Hæggström

albert.haeggstrom@nanoform.com

+358 29 370 0150

Director of Investor Relations Henri von Haartman

hvh@nanoform.com

+46 7686 650 11

FINANCIAL CALENDAR

Nov 29, 2022 - Interim report January-September 2022

Feb 28, 2023 - Annual Review 2022, Financial Statements for financial year 2022